Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: A multicenter trial

Journal of Pediatrics

Volumn 143, Issue 1, 2003, Pages 60-66

  Eugster, Erica A ^a   Rubin, Stephen D ^b   Reiter, Edward O ^b   Plourde, Paul ^b   Jou, Hann Chang ^b   Pescovitz, Ora H ^b  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FADROZOLE; GESTAGEN; GONADORELIN; KETOCONAZOLE; TAMOXIFEN; TESTOLACTONE;

ALBRIGHT SYNDROME; ANAMNESIS; ARTICLE; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; ECHOGRAPHY; FEMALE; GROWTH RATE; HORMONE BLOOD LEVEL; HUMAN; MULTICENTER STUDY; OVARY; PELVIS; PHYSICAL EXAMINATION; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; SIDE EFFECT; UTERUS; VAGINA BLEEDING;

EID: 0041353103     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(03)00128-8     Document Type: Article

References (25)

1. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 1937;216:727-46.
2. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Speigel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1655-95.
3. Collins MT, Shenker A. McCune-Albright syndrome: new insights. Curr Opin Endocrinol Diabetes 1999;6:119-25.
4. Foster CM, Feuillan P, Padmanabhan V, Pescovitz OH, Beitins IZ, Comite F, et al. Ovarian function in girls with McCune-Albright syndrome. Pediatr Res 1986;20:859-63.
5. Feuillan PP. McCune-Albright syndrome. Curr Ther Endocrinol Metab 1997;6:235-9.
6. DiMartino-Nardi J. Safety and efficacy of tamoxifen therapy in a two year old girl with McCune-Albright syndrome [abstract]. Endo Society 2000;522:2156.
7. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab 1999;12:681-6.
8. Starzyk J, Dziatkowiak H, Starzyk B, Janus D. Tamoxifen treatment in girls with progressive precocious puberty due to McCune-Albright syndrome and recurrent ovarian cysts-preliminary results [abstract P2-858]. Pediatr Res. 2001;49(Suppl 2):144A.
9. Roche AF, Chumlea WC, Thissen D. Assessing the skeletal maturity of the hand-wrist: Fels method. Springfield, Ill: Charles C Thomas; 1988.
10. Buzi F, Pilotta A, Dordani D, Lombardi A, Zaglio S, Adlard P. Pelvic ultrasonography in normal girls and in girls with pubertal precocity. Acta Paediatr 1998;87:1138-45.
11. Foster CM, Comite F, Pescovitz OH, Ross JL, Loriaux DL, Cutler GB. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 1984;59:801-5.
12. Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol 1999;12:81-3.
13. Adan L, Couto-Silva AC, Pinto G, Trivin C, Brauner R. McCune-Albright syndrome (MCAS): a review of 5 cases [abstract P2-85]. Pediatr Res 2001;49(Suppl 2):144A.
14. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986;315:1115-9.
15. Feuillan PP, Jones J, Cutler GB. Long term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. N Engl J Med 1993;77:647-51.
16. Nunez SB, Feuillan PP, Jones J, Cutler GB Jr. The aromatase inhibitor fadrozole is not an effective treatment for the precocious puberty in the McCune-Albright syndrome [abstract]. Endo Society 1997:413.
17. Laven JSE, Lumbroso S, Sultan C, Fauser BCJM. Dynamics of ovarian function in an adult woman with McCune-Albright syndrome. J Clin Endocrinol Metab 2001;86:2625-30.
18. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Can Inst 2001;93:1449-57.
19. De Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M, et al. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J Pediatr Endocrinol Metab 1999;12:817-26.
20. Schmidt H, Kiess W. Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab 1998;11:77-81.
21. McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD. Definition of the molecular and cellular mechanisms underlying the tissue-specific agonist/antagonist activities of selective estrogen receptor modulators. Rec Prog Horm Res 2002;57:295-316.
22. Sutherland RL, Murphy LC, SanFoo M, Green MD. High affinity anti-oestrogen binding site distinct from the estrogen receptor. Nature 1980;288:273-5.
23. Rodens K, Mueller M, Teller WM. Clinical, hormonal and sonographical characteristics of remission during treatment of pseudoprecocious puberty in the McCune-Albright syndrome: a longitudinal study [abstract 186]. Acta Endocrinologica 1989;120:172-3.
24. Honig SF, Wysowski DK, Beitz J. Uterine sarcoma and tamoxifen: poor prognosis compared to endometrial adenocarcinoma [abstract]. Proc ASCO 2002;21:41a.
25. Scanlon EF, Burkett FE, Sener SF, Green OC, Traisman HS, Marr TJ, et al. Breast carcinoma in an 11 year old girl with Albright's syndrome. Breast 1980;6:6-10.